Thyroid Disorders in Patients Treated with Dimethyl Fumarate for Multiple Sclerosis: A Retrospective Observational Study
Background: Dimethyl fumarate (DMF), a drug used for the treatment of multiple sclerosis (MS) and psoriasis, has been shown to activate the Keap1/Nrf2 antioxidant response. Nrf2 exerts pleiotropic roles in the thyroid gland; among others, single nucleotide polymorphisms (SNPs) in the gene encoding N...
Saved in:
Main Authors: | Cédric O. Renaud (Author), Panos G. Ziros (Author), Amandine Mathias (Author), Caroline Pot (Author), Gerasimos P. Sykiotis (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Keap1/Nrf2 Signaling Pathway in the Thyroid-2020 Update
by: Christina Thanas, et al.
Published: (2020) -
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations
by: Prosperini L, et al.
Published: (2016) -
Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate
by: Nicholas JA, et al.
Published: (2014) -
The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis
by: Roberto De Masi, et al.
Published: (2021) -
Dimethyl fumarate for treating Papillon-Lefèvre syndrome
by: Abdullah Al-Omair, MD, et al.
Published: (2023)